Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 18;11:427–440. doi: 10.2147/OTT.S149908

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Li et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

H19 acts as a competing endogenous RNA (ceRNA) that sequesters miR-370-3p. (A) Predicted duplex formation between the wild-type or mutant H19 and miR-370-3p. (B) MiR-370-3p expression levels in SKOV-3 and OVCAR3 cells after pretransfection with NC siRNA, H19 siRNA, pcDNA3.0, or pcDNA-H19 for 24 h, followed by treatment with 5 ng/mL of TGF-β1 for 48 h. (C and D) Luciferase activity of reporters with wild-type or mutant H19 sequences cotransfected with miR-NC, miR-370-3p, NC inhibitor, or miR-370-3p inhibitor into SKOV-3 (C) and OVCAR3 cells (D). Results were obtained in three independent experiments conducted in triplicate. Data are expressed as mean ± SD, *P<0.05.

Abbreviations: NC, negative control; TGF-β1, transforming growth factor-β1.